Evidence map›Paper›PMID 32229720›Full record

ArticleJCI insight2020

Glucose in the hypothalamic paraventricular nucleus regulates GLP-1 release.

Yue Ma, Risheka Ratnasabapathy, Ivan De Backer, Chioma Izzi-Engbeaya, Marie-Sophie Nguyen-Tu, Joyceline Cuenco, Ben Jones, Christopher D John, Brian Yh Lam, Guy A Rutter and 3 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Yue MaSection of Endocrinology and Investigative Medicine and.
Risheka RatnasabapathySection of Endocrinology and Investigative Medicine and.
Ivan De BackerSection of Endocrinology and Investigative Medicine and.
Chioma Izzi-EngbeayaSection of Endocrinology and Investigative Medicine and.
Marie-Sophie Nguyen-TuSection of Cell Biology and Functional Genomics, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
Joyceline CuencoSection of Endocrinology and Investigative Medicine and.
Ben JonesSection of Endocrinology and Investigative Medicine and.
Christopher D JohnSection of Endocrinology and Investigative Medicine and.
Brian Yh LamUniversity of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom.
Guy A RutterSection of Cell Biology and Functional Genomics, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
Giles Sh YeoUniversity of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom.
Waljit S DhilloSection of Endocrinology and Investigative Medicine and.
James GardinerSection of Endocrinology and Investigative Medicine and.
American Society for Investigative Pathology · USImperial College London · GBUniversity of Cambridge · GB

Funding

Biotechnology and Biological Sciences Research CouncilMedical Research Council MC_UU_00014/5Medical Research Council MC_UU_12012/1Medical Research Council MC_UU_12012/5Medical Research Council MRC_MC_UU_12012/1Medical Research Council MRC_MC_UU_12012/5Medical Research Council MR/J0003042/1Medical Research Council MR/K023667/1Medical Research Council MR/L020149/1Medical Research Council MR/L02036X/1Medical Research Council MR/M004171/1Medical Research Council MR/N00275X/1Medical Research Council MR/N020472/1Medical Research Council MR/R022259/1Medical Research Council MR/S026193/1Wellcome TrustWellcome Trust 100574/Z/12/ZWellcome Trust WT098424AIAWellcome Trust WT212625/Z/18/Z
6 · The paper itself

Abstract

Glucokinase (GK) is highly expressed in the hypothalamic paraventricular nucleus (PVN); however, its role is currently unknown. We found that GK in the PVN acts as part of a glucose-sensing mechanism within the PVN that regulates glucose homeostasis by controlling glucagon-like peptide 1 (GLP-1) release. GLP-1 is released from enteroendocrine L cells in response to oral glucose. Here we identify a brain mechanism critical to the release of GLP-1 in response to oral glucose. We show that increasing expression of GK or injection of glucose into the PVN increases GLP-1 release in response to oral glucose. On the contrary, decreasing expression of GK or injection of nonmetabolizable glucose into the PVN prevents GLP-1 release. Our results demonstrate that gluco-sensitive GK neurons in the PVN are critical to the response to oral glucose and subsequent release of GLP-1.

Indexed as

AnimalsGlucagon-Like Peptide 1GlucokinaseGlucoseMaleParaventricular Hypothalamic NucleusRatsRats, Inbred WFGlucagon-Like Peptide 1GlucokinaseGlucoseDiabetesEndocrinologyGlucose metabolismNeurosciencePeptides

Identifiers

PMID32229720
PMCPMC7205434
OpenAlexW3013900383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.